MY187848A - Anti-c5 antibodies and methods of use - Google Patents
Anti-c5 antibodies and methods of useInfo
- Publication number
- MY187848A MY187848A MYPI2018002581A MYPI2018002581A MY187848A MY 187848 A MY187848 A MY 187848A MY PI2018002581 A MYPI2018002581 A MY PI2018002581A MY PI2018002581 A MYPI2018002581 A MY PI2018002581A MY 187848 A MY187848 A MY 187848A
- Authority
- MY
- Malaysia
- Prior art keywords
- antibody
- present
- provides
- antibodies
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the beta chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the beta chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016120325 | 2016-06-17 | ||
| PCT/JP2017/022253 WO2017217524A1 (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY187848A true MY187848A (en) | 2021-10-26 |
Family
ID=59969459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018002581A MY187848A (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3472316A4 (en) |
| JP (3) | JP6202774B1 (en) |
| KR (2) | KR102226975B1 (en) |
| CN (3) | CN115960223A (en) |
| AU (1) | AU2017285763B2 (en) |
| BR (1) | BR112018075688A2 (en) |
| CA (1) | CA3021956A1 (en) |
| CL (1) | CL2018003573A1 (en) |
| CR (1) | CR20190013A (en) |
| EA (1) | EA201990018A1 (en) |
| IL (2) | IL300611A (en) |
| MX (2) | MX2018015030A (en) |
| MY (1) | MY187848A (en) |
| PE (2) | PE20190394A1 (en) |
| PH (1) | PH12018502354A1 (en) |
| SG (2) | SG10201800265UA (en) |
| TW (4) | TWI789369B (en) |
| UA (1) | UA126561C2 (en) |
| WO (1) | WO2017217524A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| SI2202245T1 (en) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| CN107488228A (en) | 2008-04-11 | 2017-12-19 | 中外制药株式会社 | The antigen binding molecules combined repeatedly with the antigen of multiple molecules |
| RU2658504C9 (en) | 2010-11-30 | 2018-08-21 | Чугаи Сейяку Кабусики Кайся | Antigen-binding molecule, that is capable of multiple binding with a lot of antigenic molecules |
| WO2016098356A1 (en) | 2014-12-19 | 2016-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
| CA3027487A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| UA126561C2 (en) * | 2016-06-17 | 2022-11-02 | Чугаі Сейяку Кабусікі Кайся | Anti-c5 antibodies and methods of use |
| KR20230079499A (en) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Composition for prophylaxis or treatment of il-8 related diseases |
| US20200262897A1 (en) * | 2017-10-04 | 2020-08-20 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis |
| US11365265B2 (en) | 2017-12-13 | 2022-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
| US20220177556A1 (en) * | 2018-09-06 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5 antibodies and uses thereof |
| CA3137907A1 (en) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof |
| CN113563467A (en) * | 2020-04-28 | 2021-10-29 | 上海普铭生物科技有限公司 | Antibodies against human complement protein C5 and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0230985Y2 (en) | 1985-07-08 | 1990-08-21 | ||
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| CN1322787C (en) | 2001-06-12 | 2007-06-20 | 艾利森电话股份有限公司 | Synchronisation in UMTS terrestrial radio access network (UTRAN) |
| MX342385B (en) | 2001-08-17 | 2016-09-27 | Genentech Inc | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b. |
| JP4333939B2 (en) | 2001-08-27 | 2009-09-16 | ロード・コーポレーション | Trolley wire suspension system |
| DE10253331A1 (en) | 2002-11-14 | 2004-06-03 | Symrise Gmbh & Co. Kg | Use of trans-pellitori as a flavoring |
| US7267849B2 (en) | 2004-03-02 | 2007-09-11 | Nitto Denko Corporation | Compensator for liquid crystal display |
| KR20080069889A (en) | 2007-03-20 | 2008-07-29 | (주)화도 | Pe pipe |
| WO2008113834A2 (en) * | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| EP2138531B1 (en) | 2007-04-11 | 2014-10-29 | Sekisui Chemical Co., Ltd. | Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin |
| CN107488228A (en) * | 2008-04-11 | 2017-12-19 | 中外制药株式会社 | The antigen binding molecules combined repeatedly with the antigen of multiple molecules |
| EP2837388A1 (en) * | 2008-08-05 | 2015-02-18 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
| KR20100054403A (en) | 2008-11-14 | 2010-05-25 | 삼성전자주식회사 | Online composition apparatus and method for writing by multiple participants |
| TW201206466A (en) * | 2010-03-11 | 2012-02-16 | Rinat Neuroscience Corp | Antibodies with pH dependent antigen binding |
| SG10201507722QA (en) * | 2010-03-11 | 2015-10-29 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| KR20110111007A (en) | 2010-04-02 | 2011-10-10 | 이화여자대학교 산학협력단 | Octahydro-binaphthol derivatives for l/d optical conversion and optical resolution |
| KR20110122011A (en) | 2010-05-03 | 2011-11-09 | 황보철종 | System for administrating combine store point and method therefor |
| EA028244B1 (en) * | 2012-08-13 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS |
| CN105143261B (en) * | 2013-01-31 | 2021-04-09 | 首尔大学校产学协力团 | C5 antibodies and methods for preventing and treating complement-associated diseases |
| WO2014160958A1 (en) * | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| WO2016098356A1 (en) * | 2014-12-19 | 2016-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
| MX2018007144A (en) * | 2015-12-18 | 2018-11-29 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use. |
| UA126561C2 (en) * | 2016-06-17 | 2022-11-02 | Чугаі Сейяку Кабусікі Кайся | Anti-c5 antibodies and methods of use |
-
2017
- 2017-06-16 UA UAA201810992A patent/UA126561C2/en unknown
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/en unknown
- 2017-06-16 TW TW106141573A patent/TWI789369B/en active
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/en active IP Right Grant
- 2017-06-16 TW TW106120143A patent/TWI610941B/en active
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/en active Pending
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/en unknown
- 2017-06-16 TW TW111107923A patent/TWI807666B/en active
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 EA EA201990018A patent/EA201990018A1/en unknown
- 2017-06-16 PE PE2023002969A patent/PE20240825A1/en unknown
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/en active Active
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-06-16 CR CR20190013A patent/CR20190013A/en unknown
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/en active Pending
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en active Application Filing
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/en unknown
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/en active IP Right Grant
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/en active Active
- 2017-06-16 TW TW112120479A patent/TW202337903A/en unknown
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/en active Active
-
2018
- 2018-11-08 PH PH12018502354A patent/PH12018502354A1/en unknown
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/en unknown
- 2018-12-12 IL IL263657A patent/IL263657A/en unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/en unknown
-
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501114A1 (en) | Anti-c5 antibodies and methods of use | |
| MX2023001360A (en) | Anti-c5 antibodies and methods of use. | |
| PH12018501282A1 (en) | Anti-c5 antibodies and methods of use | |
| BR112017006203A2 (en) | isolated, caninized and monoclonal antibodies or antigen binding fragment thereof, isolated nucleic acid, expression vector, host cell, isolated antigenic peptide, fusion protein, pharmaceutical composition, and method of enhancing the activity of an immune cell. | |
| MX2017001401A (en) | Optimized cross-species specific bispecific single chain antibody constructs. | |
| BR112016014284A2 (en) | isolated caninized antibody or antigen binding fragment thereof, isolated nucleic acid, expression vector, host cell, pharmaceutical composition, and methods for enhancing the activity of an immune cell and for producing a caninized antibody or antigen binding fragment the same | |
| EA035160B9 (en) | Anti-st2 antibodies and use thereof | |
| BR112016014022A2 (en) | anti-cd3 antibodies, isolated nucleic acid, vector, host cell, anti-cd3 antibody production method, immunoconjugate, composition, use of anti-cd3 antibody, treatment methods, methods of enhancing immune function and kit | |
| EA201591131A1 (en) | DNA STRUCTURE ANTIBODY AND METHOD OF THEIR APPLICATION | |
| MY188761A (en) | Method of reducing serum levels of fc-containing agents using fcrn antagonists | |
| MX2018011425A (en) | Dna antibody constructs and method of using same. | |
| MX2018013520A (en) | Dna monoclonal antibodies targeting checkpoint molecules. | |
| EA201690171A1 (en) | IMPROVED METHOD OF OBTAINING MONOCLONAL ANTIBODIES | |
| AR082518A1 (en) | ANTIBODIES AGAINST IL-18R1 AND USES OF THE SAME | |
| BR112015023262A2 (en) | isolated antibody, isolated nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation and uses of the antibody | |
| GB201003701D0 (en) | System for the expression of a protein | |
| PH12018501070A1 (en) | Anti-pcsk9 antibody and use thereof | |
| ZA202104048B (en) | Anti-il-17a antibody and use thereof | |
| MX2018013523A (en) | Dna monoclonal antibodies targeting il-6 and cd126. | |
| AU2017261305A8 (en) | DNA monoclonal antibodies targeting influenza virus | |
| WO2019075300A3 (en) | Mayaro virus consensus antigens, dna antibody constructs for use against mayaro virus, and combinations thereof | |
| EA201500546A1 (en) | MONOCLONAL ANTI-D ANTIBODIES WITH HIGH AFFINITY TO LOW AFFFIN Fcgamma RECEPTORS | |
| TH154333A (en) | A monoclonal antibody specific to the 1-30 amino acid sequence of Mig7 protein and its application. |